Search Result

Results for "

CPD

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Anaplastic lymphoma kinase (ALK) (1) Apolipoprotein (1) Apoptosis (2) CDK (3) DNA/RNA Synthesis (1) Drug Derivative (3) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (2) Endogenous Metabolite (1) Epigenetic Reader Domain (2) Ferroptosis (1) FGFR (1) Histone Acetyltransferase (2) IRE1 (1) Isotope-Labeled Compounds (1) JAK (2) Ligands for Target Protein for PROTAC (2) Mps1 (1) PARP (2) PD-1/PD-L1 (1) Potassium Channel (1) PROTAC Linkers (2) PROTACs (4) Reference Standards (1) Sex Pheromone (1) Small Interfering RNA (siRNA) (4) STAT (1) TAM Receptor (1) Toll-like Receptor (TLR) (1) Trk Receptor (1) VEGFR (1)
By Research Areas:	Cancer (25) Cardiovascular Disease (2) Endocrinology (1) Infection (2) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-168660

CPD-10 1 Publications Verification	PROTACs Apoptosis CDK	Cancer
CPD-10 is a potent CCND1 and CDK4 PROTAC degrader. CPD-10 exhibits anti-proliferative effects on tumor cells and can also induce apoptosis. CPD-10 can be used for the study of breast cancer and lung cancer .

HY-153386

CPD-1224	Anaplastic lymphoma kinase (ALK)	Cancer
CPD-1224 is an orally effective ALK inhibitor, a derivative of an ALK inhibitor that connects to the cereblon ligand. CPD-1224 targets the EML4-ALK oncogenic fusion protein and degrades both ALK and the mutant forms L1196M/G1202R. CPD-1224 can slow down tumor growth .

HY-112338

C188 CPD188	STAT Apoptosis	Cancer
C188 (CPD188) is a STAT3 inhibitor with anticancer effects. C188 inhibits STAT3 SH2/pY-peptide binding (IC₅₀ of 20 µM against pY-peptide binding) and IL-6-mediated STAT3 phosphorylation. C188 is selective for STAT3 over STAT1. C188 inhibits nuclear-to-cytoplasmic translocation of Stat3. C188 shows highly active induces apoptosis in breast cancer cell lines with constitutive Stat3 activation (EC₅₀s of 0.73 µM, 3.96 µM, and 7.01 µM in MDA-MB-468, MDA-MB-231, and MDA-MB-435 cultures, respectively) .

HY-158009

SGF29-IN-1 1 Publications Verification	Histone Acetyltransferase	Cancer
SGF29-IN-1 (Compound Cpd_DC60) is a selective inhibitor for Spt-Ada-Gcn5 acetyltransferase (SAGA)–associated factor 29 (SGF29)-Tudor domain. SGF29-IN-1 exhibits activity against leukemia .

HY-168664

CPD-39	PROTACs CDK	Cancer
CPD-39 is a potent and orally active CCND1 and CDK4 heterobifunctional PROTAC degrader. CPD-39 shows anti-proliferation. (Pink: ligand for target protein (HY-50767); black: linker (HY-20240); Blue: E3 ligase ligand (HY-168667)) .

HY-P990114

Anti-Canine PD-L1/B7-H1 Antibody (JC071)	PD-1/PD-L1	Others
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine PD-L1/B7-H1 IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .

HY-158142

PROTAC TYK2 degrader-1	PROTACs JAK	Inflammation/Immunology Cancer
PROTAC TYK2 degrader-1 (CPD-155) is a PROTAC targeting degrader to TYK2 with D_max >60%.

HY-W585819

3-Chloropropane-1,2-diol dipalmitate 3-MPCD dipalmitate; 3-CPD dipalmitate	Drug Derivative	Others
3-Chloropropane-1,2-diol dipalmitate (3-MPCD dipalmitate) is a fatty acid ester of 3-monochloropropane-1,2-diol (3-MCPD) and a foodborne contaminant .

HY-22391

tert-Butyl (7-aminoheptyl)carbamate tert-Butyl 2,8-diaminooctanoate	PROTAC Linkers	Cancer
tert-Butyl (7-aminoheptyl)carbamate (tert-Butyl 2,8-diaminooctanoate) is a PROTAC linker. tert-Butyl (7-aminoheptyl)carbamate can be used to synthesis CPD-10 (HY-168660) .

HY-163705

*BR-cpd7*	PROTACs FGFR	Cancer
BR-cpd7 is a PROTAC degrader for fibroblast growth factor receptor FGFR1/2 with DC₅₀ of 10 nM. BR-cpd7 arrests cell cycle, inhibits proliferations of FGFR1/2 aberrant activated tumor cells. (Pink: ligand for target protein FGFR-IN-12 (HY-160013); Black: linker; Blue: ligand for E3 ligase Thalidomide-NH-CH2-COOH (HY-131717))

HY-143498

ERCC1-XPF-IN-1	DNA/RNA Synthesis	Cancer
ERCC1-XPF-IN-1 is a potent and high-affinity ERCC1-XPF inhibitor with IC₅₀ value of 0.49 μM. ERCC1-XPF-IN-1 has the capacity to potentiate the cytotoxicity effect of UV radiation and inhibiting DAN repair, by the inhibition of removal of CPDs, and cyclophosphamide toxicity to colorectal cancer cells .

HY-174416

Smurf1-IN-5	E1/E2/E3 Enzyme	Cardiovascular Disease
Smurf1-IN-5 (Compound cpd-6) is an allosteric SMAD ubiquitin regulatory factor 1 (SMURF1) inhibitor. Smurf1-IN-5 leads to a reduction in the ubiquitylation of substrates such as BMPR2 (bone morphogenetic protein receptor 2) and SMAD1, enhancing the BMP (bone morphogenetic protein) signaling pathway. Smurf1-IN-5 is promising for research of pulmonary arterial hypertension (PAH) .

HY-147310

*CU-CPD107*	Toll-like Receptor (TLR)	Infection
CU-CPD107 is a potent, selective toll-like receptor 8 (TLR 8) agonist. CU-CPD107 inhibits TLR8 signaling. CU-CPD107 converts to synergistic agonist activities in the presence of ssRNA and induces TLR8 signaling. CU-CPD107 inhibits proinflammatory factor expression and avoids immune responses in the presence of ssRNA .

HY-174991

CPD-2828	IRE1	Neurological Disease Cancer
CPD-2828 is an orally active and selective IRE1α inhibitor with an IC₅₀ value of 1.2 μM. CPD-2828 is promising for research of endoplasmic reticulum stress-related diseases (e.g., cancer, neurodegenerative diseases) .

HY-N7893

*Ebracteolata cpd* B**	Others	Others
Ebracteolata cpd B is a natural phenol compound found in Euphorbia ebracteolata .

HY-161606

PARP-1/2/7-IN-1	PARP	Cancer
PARP-1/2/7-IN-1 (compound 86) is a potent inhibitor of PARP-1/2/7, with the IC₅₀ of ＜ 10 nM .

HY-161607

PARP7-IN-21	PARP	Cancer
PARP7-IN-21 (compound 128) is a potent inhibitor of PARP7, with the IC₅₀ of ＜ 10 nM .

HY-176927

ADC-VI	Drug-Linker Conjugates for ADC	Cancer
ADC-VI (Compound 6) is a conjugate of a toxic molecule and a linker, in which the cytotoxin carried by CPD6 is Deruxtecan (HY-13631E). Tricyclene is used to form an antibody-drug conjugate (ADC) by a chemical conjugation reaction through linking with an anti-FGFR2b antibody .

HY-163533

CPD-002	VEGFR	Inflammation/Immunology
CPD-002 is an inhibitor for vascular endothelial growth factor receptor 2 (VEGFR 2), that inhibits angiogenesis through inhibition of VEGFR2/PI3K/AKT signaling pathway. CPD-002 exhibits anti-inflammatory activity and attenuates rheumatoid arthritis .

HY-171786

CDK12-IN-8	CDK	Cancer
CDK12-IN-8 (Compound Cpd143) is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). CDK12-IN-8 inhibits CDK12-mediated phosphorylation of the C-terminal domain (CTD) serine 2 of RNA polymerase II, interfering with gene transcription elongation and DNA damage repair pathways. CDK12-IN-8 is promising for research of cancers with high CDK12 expression such as small cell lung cancer and triple-negative breast cancer .

HY-RS03089

CPD Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CPD Human Pre-designed siRNA Set A contains three designed siRNAs for CPD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CPD Human Pre-designed siRNA Set A CPD Human Pre-designed siRNA Set A

HY-168662

Palbociclib-CH2COOH	Ligands for Target Protein for PROTAC	Cancer
Palbociclib-CH2COOH is a Ligands for Target Protein for PROTACs. Palbociclib-CH2COOH can serve as an active control for the target protein ligand of CPD-39 (HY-168664) and CPD-10 (HY-168660) .

HY-144028

Pan-Trk-IN-2	Trk Receptor	Cancer
Compound cpd-1 is a small molecule Trks inhibitor with good antitumor activity .

HY-RS06284

HOMER2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HOMER2 Human Pre-designed siRNA Set A contains three designed siRNAs for HOMER2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HOMER2 Human Pre-designed siRNA Set A HOMER2 Human Pre-designed siRNA Set A

HY-158340

TYK2 ligand 1	JAK Ligands for Target Protein for PROTAC	Cancer
TYK2 ligand 1 is a TYK2 ligand in the synthesis of PROTAC-based TYK2 degrader (CPD-155, HY-158142) .

HY-168668

E3 Ligase Ligand-linker Conjugate 132	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 132 is a conjugate of E3 ligase ligand and linker that serve as a key intermediate for the synthesis of complete PROTAC molecule CPD-39 (HY-168664) .

HY-168663

E3 Ligase Ligand-linker Conjugate 131	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 131 is a conjugate of E3 ligase ligand and linker that serve as a key intermediate for the synthesis of complete PROTAC molecule CPD-10 HY-168660 .

HY-20240

tert-Butyl (6-aminospiro[3.3]heptan-2-yl)carbamate	PROTAC Linkers	Cancer
tert-Butyl (6-aminospiro[3.3]heptan-2-yl)carbamate is a linker that can be used for synthesis of PROTAC degrader CPD-39 (HY-168664) .

HY-134621

P300-IN-1	Histone Acetyltransferase	Cancer
P300-IN-1 (cpd205) is a Histone acetylase p300 inhibitor .

HY-153441

AXL-IN-15	TAM Receptor	Cancer
AXL-IN-15 (cpd391) is a potent Axl inhibitor with both K_i and IC₅₀ <1 nM. AXL-IN-15 can be used for research in cancer .

HY-P4914

Sex Pheromone Inhibitor iPD1	Sex Pheromone	Others
Sex Pheromone Inhibitor iPD1 is a sex pheromone inhibitor. Sex Pheromone Inhibitor iPD1 inhibits the sex pheromone cPD1 .

HY-P4523

FA-Ala-Arg	Endogenous Metabolite	Endocrinology
FA-Ala-Arg is a dipeptide with furylacryloyl group. FA-Ala-Arg breaks down to produce arginine. While cell-surface Carboxypeptidase-D (CPD) also increases intracellular Arg, which is converted to nitric oxide (NO). FA-Ala-Arg enhances NO production in MCF-7 cells. FA-Ala-Arg also increases the cell survival of prolactin (PRL)-treated cells, PRL regulates CPD mRNA levels in cells .

HY-W585819R

3-Chloropropane-1,2-diol dipalmitate (Standard) 3-MPCD dipalmitate (Standard); 3-CPD dipalmitate (Standard)	Reference Standards Drug Derivative	Others
3-Chloropropane-1,2-diol dipalmitate (3-MPCD dipalmitate) Standard is the analytical standard of 3-Chloropropane-1,2-diol dipalmitate (HY-W585819). This product is intended for research and analytical applications. 3-Chloropropane-1,2-diol dipalmitate (3-MPCD dipalmitate) is a fatty acid ester of 3-monochloropropane-1,2-diol (3-MCPD) and a foodborne contaminant .

HY-W471937

α1B-AR antagonist 1	Adrenergic Receptor	Cardiovascular Disease Neurological Disease
α1b-AR antagonist 1 (Compound Cpd1) is a selective α₁B-AR antagonist. Alpha1b-ar antagonist 1 can be used in the study of cardiovascular and central nervous system diseases .

HY-179364

PLTP-IN-1	Apolipoprotein	Metabolic Disease
PLTP-IN-1 (cpd B) is a selective phospholipid transfer protein (PLTP) inhibitor with an IC₅₀ of 1.6 μM. PLTP-IN-1 can block the phospholipid transfer mediated by PLTP and reduce the secretion of apolipoprotein B. PLTP-IN-1 has no effect on the level of triglycerides. PLTP-IN-1 can be used for the research of metabolic disease, such as hyperlipidemia .

HY-178488

BRM/BRG1 ATP-IN-7	Epigenetic Reader Domain	Infection Cancer
BRM/BRG1 ATP-IN-7 (Compound Cpd69) is a selective dual BRM (SMARCA2) and BRG1 (SMARCA4) inhibitor with IC₅₀ values of 12 nM and 8 nM, respectively. BRM/BRG1 ATP-IN-7 is promising for research of BRM/BRG1-dependent cancers (e.g., non-small cell lung cancer, Ewing sarcoma) and virus-associated diseases (e.g., HPV infection) .

HY-172455

TREK inhibitor-3	Potassium Channel	Neurological Disease
TREK inhibitor-3 (Cpd8l) is a selective and BBB-permeable TREK-1 inhibitor with an IC₅₀ of 0.81 μM. TREK inhibitor-3 has neuroprotective effects, which can significantly reduce the death of cortical neurons induced by oxygen-glucose deprivation/reoxygenation (OGD/R) and improve brain injury in mice models of middle cerebral artery occlusion/reperfusion (MCAO/R). TREK inhibitor-3 can be used in the research of ischemic stroke .

HY-W585819S

3-Chloropropane-1,2-diol dipalmitate-13C3 3-MPCD dipalmitate-¹³C₃; 3-CPD dipalmitate-¹³C₃	Isotope-Labeled Compounds Drug Derivative	Others
3-Chloropropane-1,2-diol dipalmitate- ¹³C₃ (3-MPCD dipalmitate- ¹³C₃) is ¹³C labeled 3-Chloropropane-1,2-diol dipalmitate (HY-W585819). 3-Chloropropane-1,2-diol dipalmitate (3-MPCD dipalmitate) is a fatty acid ester of 3-monochloropropane-1,2-diol (3-MCPD) and a foodborne contaminant .

HY-178490

BRM/BRG1 ATP-IN-8	Epigenetic Reader Domain	Cancer
BRM/BRG1 ATP-IN-8 (Compound Cpd14) is an orally active BRG1/BRM ATPase domain inhibitor. BRM/BRG1 ATP-IN-8 exerts antitumor effects by disrupting aberrant chromatin remodeling in cancer cells, inducing apoptosis and growth arrest. BRM/BRG1 ATP-IN-8 is promising for research of BRG1/BRM-dependent malignancies, including hematological cancers, prostate cancer, breast cancer, and Ewing's sarcoma .

HY-169059

Ferroptosis-IN-12	Ferroptosis	Inflammation/Immunology
Ferroptosis-IN-12 (Cpd-A1) is a ferroptosis inhibitor. Ferroptosis-IN-12 exhibits effective ferroptosis inhibition in Erastin (HY-15763)-treated mouse tubular epithelial cells (mTECs) and improves kidney function, alleviates renal tubular damage, and reduces inflammation in a dose-dependent manner in acute kidney injury (AKI) mouse models induced by ischemia/reperfusion (I/R) or cecal ligation and puncture (CLP). Ferroptosis-IN-12 demonstrates good plasma stability and high distribution in kidney tissues in pharmacokinetic studies in mice. Ferroptosis-IN-12 holds promise for research in the field of acute kidney injury (AKI) .

HY-RS18891

Cpd Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cpd Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cpd gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cpd Mouse Pre-designed siRNA Set A Cpd Mouse Pre-designed siRNA Set A

HY-RS25382

Cpd Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cpd Rat Pre-designed siRNA Set A contains three designed siRNAs for Cpd gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cpd Rat Pre-designed siRNA Set A Cpd Rat Pre-designed siRNA Set A

HY-116470

Mps1/TTK-IN-1	Mps1	Cancer
Mps1/TTK-IN-1 (Compound cpd-5), a derivative of NMS-P715 (HY-12382), is a Mps1 kinase inhibitor with an IC₅₀ of 9.2 nM and a K_d of 1.6 nM. Mps1/TTK-IN-1 specifically targets the ATP-binding pocket of the Mps1 kinase. Mps1/TTK-IN-1 maintains inhibitory activity against Mps1 drug-resistant mutants (C604Y, C604W) with IC₅₀ values of 170 and 19 nM and K_d values of 471 and 349 nM. Mps1/TTK-IN-1 can block the phosphorylation of kinetochore protein KNL1 mediated by Mps1, interfere with the spindle assembly checkpoint function, prevent the correct separation of chromosomes, and thereby inhibit the mitosis and proliferation of tumor cells .

Cat. No.	Product Name	Target	Research Area